Zhou Mingshu, Liu Chongdong, Cao Guangming, Gao Huiqiao, Zhang Zhenyu
Department of Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
J Cancer Res Ther. 2019;15(2):420-425. doi: 10.4103/jcrt.JCRT_536_18.
To investigate the expression of polymeric immunoglobulin receptor (pIgR) in endometrial adenocarcinoma and the relationship between pIgR and the clinicopathological features of endometrial adenocarcinoma. To investigate the role of pIgR in the biological behavior of endometrial adenocarcinoma cell lines.
First, the paraffin-embedded endometrial adenocarcinoma samples and clinicopathological data from the Chao-Yang Hospital were collected. Next, immunohistochemistry was conducted to test the expression of pIgR in endometrial adenocarcinoma; the correlations between pIgR and clinicopathological features were detected. Then, the expression of pIgR in the Ishikawa cells was interfered with short-interfering RNA (siRNA). Finally, the migration and proliferation abilities of Ishikawa cells were detected by transwell and CCK8 assays before and after interference.
pIgR had a high expression level and higher H-score in endometrial adenocarcinoma (P = 0.013) than in noncancerous tissues. There was no correlation between pIgR and the histopathological features of endometrial adenocarcinoma (P ≥ 0.418). The migration ability of Ishikawa cells was increased after interference with pIgR (P = 0.023). The proliferation of Ishikawa cells was not different between the untreated and siRNA215-treated groups (P = 0.967).
PIgR may be a predictive biomarker of endometrial adenocarcinoma and a potential target protein for immunotherapy of endometrial adenocarcinoma.
探讨聚合免疫球蛋白受体（pIgR）在子宫内膜腺癌中的表达及其与子宫内膜腺癌临床病理特征的关系。研究pIgR在子宫内膜腺癌细胞系生物学行为中的作用。
首先，收集朝阳医院石蜡包埋的子宫内膜腺癌样本及临床病理资料。其次，采用免疫组织化学法检测pIgR在子宫内膜腺癌中的表达；检测pIgR与临床病理特征之间的相关性。然后，用小干扰RNA（siRNA）干扰Ishikawa细胞中pIgR的表达。最后，通过transwell和CCK8检测干扰前后Ishikawa细胞的迁移和增殖能力。
与非癌组织相比，pIgR在子宫内膜腺癌中的表达水平较高且H评分更高（P = 0.013）。pIgR与子宫内膜腺癌的组织病理学特征之间无相关性（P≥0.418）。干扰pIgR后，Ishikawa细胞的迁移能力增强（P = 0.023）。未处理组和siRNA215处理组Ishikawa细胞的增殖无差异（P = 0.967）。
PIgR可能是子宫内膜腺癌的预测生物标志物，也是子宫内膜腺癌免疫治疗的潜在靶蛋白。
